Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00003145 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia | completed | Phase 2 | 18 | Fred Hutchinson Cancer CenterOTHER |
| 3 |
| Jan 10, 2020 |
| clinicaltrials |
| NCT02044796 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 199 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT01664897 | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02538965 | A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 17 | CelgeneINDUSTRY | 2 | Jan 7, 2020 | clinicaltrials |
| NCT01527045 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00669578 | CC-4047 in Treating Patients With Myelofibrosis | completed | Phase 1 / Phase 2 | 77 | Mayo ClinicOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT00723099 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | completed | Phase 2 | 73 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT00001637 | Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults | completed | Phase 2 | 28 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00003270 | Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00989261 | Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)(ACE) | completed | Phase 2 | 333 | Daiichi SankyoINDUSTRY | 9 | Dec 11, 2019 | clinicaltrials |
| NCT02017457 | Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | completed | Phase 2 | 50 | Carlos Graux, MD, PhDOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01251575 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 9, 2019 | clinicaltrials |
| NCT00185692 | Allogeneic Transplantation From Related Haploidentical Donors | completed | Phase 2 | 16 | Stanford UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT01446081 | An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy | completed | Phase 2 | 83 | University Health Network, TorontoOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT01012492 | Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | completed | Phase 2 | 11 | Boston Children's HospitalOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT01707004 | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 20 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00463385 | A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia | completed | Phase 2 | 88 | CelgeneINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00052832 | Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | completed | Phase 2 | — | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01829503 | Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 44 | Annie Im, M.D.OTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT00006350 | Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | — | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00928707 | Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera(PV) | completed | Phase 2 | 45 | ItalfarmacoINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT01702155 | Phase I/II Study of DFP-10917 in Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 69 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT00003396 | Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | 42 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT00015951 | Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | completed | Phase 2 | — | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01743859 | Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia | completed | Phase 2 | 37 | University of Colorado, DenverOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT00044954 | Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | — | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT00620321 | A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 24 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 9, 2019 | clinicaltrials |
| NCT00997386 | Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States(ALBUM) | completed | Phase 2 | 16 | University of ArizonaOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT02666950 | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02474290 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | completed | Phase 2 / Phase 3 | 202 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01901432 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | completed | Phase 1 / Phase 2 | 48 | ItalfarmacoINDUSTRY | 5 | Jul 30, 2019 | clinicaltrials |
| NCT02447666 | Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 2 | 28 | CelgeneINDUSTRY | 13 | Jul 11, 2019 | clinicaltrials |
| NCT00510133 | A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 21 | Asterias Biotherapeutics, Inc.INDUSTRY | 1 | Jul 9, 2019 | clinicaltrials |
| NCT00946270 | Pomalidomide for Myelofibrosis Patients | completed | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT01294618 | Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia(NILOPEG) | completed | Phase 2 | 60 | Hospices Civils de LyonOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT00895934 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2019 | clinicaltrials |
| NCT00414310 | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 153 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT00475020 | Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | completed | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02311569 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | completed | Phase 2 | 39 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00413166 | All-trans Retinoic Acid, and Arsenic +/- Idarubicin | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01392989 | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | completed | Phase 2 | 44 | Everett MeyerOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT00397579 | DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT00796562 | Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy | completed | Phase 2 | 107 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 18, 2020source: clinicaltrials